Helicobacter pylori infection
Conditions
Interventions
VAST-10:VA dual sequential therapy for 10 days
VAST-14:VA dual sequential therapy for 14 days
VADT-14:VA dual therapy for 14 days
Sponsors
Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1?Aged 18-70 years, gender unrestricted. 2? Chronic gastritis patients with Helicobacter pylori positivity: (1) Helicobacter pylori positive is defined as a positive result on a carbon-13 or carbon-14 breath test within one month prior to enrollment; (2) Chronic gastritis is defined as a diagnosis based on gastroscopy within six months prior to enrollment. 3?No previous Helicobacter pylori eradication therapy. 4?Agree to participate in the trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Allergy to any of the drugs used in this clinical trial. 2.Previously received H. pylori eradication treatment. 3.Receiving Potassium-competitive acid blocker (P-CAB), proton pump inhibitor (PPI), H2 receptor antagonist, antibiotics, bismuth, probiotic preparations 4 weeks before initiating study treatment. 4.Use of non-steroidal anti-inflammatory drugs (NSAIDs), adrenal corticosteroids, or anticoagulants during the study period. 5. Pregnant or lactating women, or patients planning to conceive during the study period. 6. Patients with hepatic or renal dysfunction, or those with severe concomitant diseases that may affect the evaluation of this study, such as heart disease, lung disease, liver disease, kidney disease, metabolic disorders, mental illnesses, malignant tumors, etc.. 7.Gastroscopy findings indicating conditions other than gastritis, such as reflux esophagitis, which require continued use of potassium-competitive acid blockers (P-CABs), proton pump inhibitors (PPIs), H2 receptor antagonists, or bismuth after Helicobacter pylori eradication. 8.Patients with a history of gastric surgery. 9. Patients who are unable to accurately express their symptoms, such as those with psychiatric disorders or severe neurosis, and are unable to cooperate with the trial. 10.Patients who have participated in other drug studies within 3 months before using the investigational drug. 11.Other conditions deemed by the investigator as unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H. pylori eradication rate;Patient compliance;Cost-effectiveness ratio; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events; | — |
Countries
China
Contacts
Public ContactFeng Ye
Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Outcome results
None listed